Trials / Active Not Recruiting
Active Not RecruitingNCT04161898
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Upadacitinib in Subjects With Takayasu Arteritis (SELECT-Takayasu)
- Status
- Active Not Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the efficacy of upadacitinib in combination with a corticosteroid taper regimen compared to placebo in combination with a corticosteroid taper regimen.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Upadacitinib | Upadacitinib will be administered as oral tablet |
| DRUG | Placebo for Upadacitinib | Placebo for upadacitinib will be administered as oral tablet |
| DRUG | Prednisolone | Prednisolone will be administered as oral tablet |
Timeline
- Start date
- 2020-02-04
- Primary completion
- 2028-08-01
- Completion
- 2028-08-01
- First posted
- 2019-11-13
- Last updated
- 2026-02-18
Locations
48 sites across 6 countries: Argentina, Brazil, China, Japan, South Korea, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04161898. Inclusion in this directory is not an endorsement.